Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer
- PMID: 31206626
- PMCID: PMC7376605
- DOI: 10.1002/cncr.32083
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer
Abstract
Background: Breast cancer (BC) is the most common cancer and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 and BRCA2 (BRCA) mutations explain less than one-half of hereditary BC, and the proportion associated with other BC susceptibility genes is unknown.
Methods: Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
Results: Forty-nine (4.6%) pathogenic or likely pathogenic variants (PVs) in 47 of 1054 participants (4.5%), including 21 truncating frameshift, 20 missense, 5 nonsense, and 4 splice variants, were identified in CHEK2 (n = 20), PALB2 (n = 18), ATM (n = 5), TP53 (n = 3), BRIP1 (n = 2), and CDH1 and NF1 (both n = 1) and none were identified in NBN, PTEN, STK11, RAD51C, or RAD51D. Nine participants carried the PALB2 c.2167_2168del PV (0.85%), and 14 carried the CHEK2 c.707T>C PV (1.32%).
Conclusions: Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurrent PVs in PALB2 and CHEK2 represented 47% (23 of 49) of the total, suggesting a founder effect. Accurate classification of variants was enabled by carefully controlling for ancestry and the increased identification of at-risk Hispanics for screening and prevention.
Keywords: Hispanics; breast cancer; checkpoint kinase 2 (CHEK2); disparities; ovarian cancer; partner and localizer of BRCA2 (PALB2); whole-exome sequencing.
© 2019 American Cancer Society.
Conflict of interest statement
There are no conflict of interest disclosures from any authors.
Comment in
-
Genetic testing for breast cancer in the Hispanic community.Cancer. 2019 Aug 15;125(16):2728-2729. doi: 10.1002/cncr.32334. Epub 2019 Jun 17. Cancer. 2019. PMID: 31206622 No abstract available.
References
-
- Colby S L MOJ Projection of the Size and Composition of the U.S. Population: 2014 to 2060. In: Administration USDoCEaS, ed. Washington, DC: 2015.
-
- Huerta EE. Cancer statistics for Hispanics, 2003: Good news, bad news, and the need for a health system paradigm change. CA Cancer J Clin. 2003;53(4):205–207. - PubMed
-
- Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Journal of the National Cancer Institute. 2005;97(6):439–448. - PubMed
-
- Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015;16(14):1405–1438. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- UM1 CA164973/CA/NCI NIH HHS/United States
- R01 CA184585/CA/NCI NIH HHS/United States
- R01 CA063464/CA/NCI NIH HHS/United States
- P30 CA014089/CA/NCI NIH HHS/United States
- R50 CA211280/CA/NCI NIH HHS/United States
- U01 CA063464/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- R01 CA054281/CA/NCI NIH HHS/United States
- K08 CA234394/CA/NCI NIH HHS/United States
- P30 CA033572/CA/NCI NIH HHS/United States
- U01 CA164973/CA/NCI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- K24 CA169004/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
